Ocrelizumab-induced Psoriasis in A Patient with Relapsing-Remitting Multiple Sclerosis



Abstract Views
458

Downloads
480

Citations

Share

##plugins.themes.bootstrap3.article.sidebar##

Submitted Feb 25, 2023
Published May 2, 2023
10.24018/ejmed.2023.5.3.1697

Abstract viewed = 458 times

Table of Contents

##plugins.themes.bootstrap3.article.main##

Background: Ocrelizumab is widely used as a Disease Modifying Drug (DMD) in Multiple sclerosis. The complete side effects are yet not known.

Materials and Methods: We describe a 34-year-old female with longstanding relapsing-remitting Multiple Sclerosis for whom Ocrelizumab was started as an escalation therapy. She reported severe itchy and patchy lesions two months after the first full dose of Ocrelizumab. Pathohistological findings revealed the diagnosis of guttate psoriasis. Psoriasis continued to flare against treatment with topical steroids, and UV therapy and progressed to developed arthritis psoriasis.

Results: Treatment escalated to an IL-17 antagonist (Secukinumab), with a favorable outcome. Ocrelizumab was discontinued. After one year of follow-up, the patient remained stable from an MS standpoint.

Conclusion: This is the third report showing the possible cutaneous side effect of Ocrelizumab.

Keywords: Multiple sclerosis Ocrelizumab psoriasis side effect

Downloads

Download data is not yet available.

References

  1. Merola JF, Li T, Li WQ, Cho E, Qureshi AA. Prevalence of psoriasis phenotypes among men and women in the USA. Clinical and Experimental Dermatology. 2016; 41(5): 486-9.
    DOI  |   Google Scholar
  2. Egeberg A, Mallbris L, Gislason GH, Skov L, Hansen PR. Risk of multiple sclerosis in patients with psoriasis: a Danish nationwide cohort study. Journal of Investigative Dermatology. 2016; 136(1): 93-8.
    DOI  |   Google Scholar
  3. Lambrianides S, Kinnis E, Leonidou E, Pantzaris M. Does natalizumab induce or aggravate psoriasis? A case study and review of the literature. Case Reports in Neurology. 2018; 10(3): 286-91.
    DOI  |   Google Scholar
  4. Faissner S, Gold R. Efficacy and safety of multiple sclerosis drugs approved since 2018 and future developments. CNS Drugs. 2022; 36(8): 803-17.
    DOI  |   Google Scholar
  5. Geilsπ HM, Katzπ JD, Lathiπ ES, Striblingπ IC. Psoriasis Exacerbation during Ocrelizumab Therapy for Relapsing Multiple Sclerosis: A Case Report. 2019.
     Google Scholar
  6. Jakob Brecl G, Gabelić T, Ruška B, Horvat Ledinek A, Habek M. Psoriasis caused by ocrelizumab in two persons with primary progressive multiple sclerosis. International Journal of Dermatology. 2022; 61(9): e322-4.
    DOI  |   Google Scholar
  7. Guidelli GM, Fioravanti A, Rubegni P, Feci L. Induced psoriasis after rituximab therapy for rheumatoid arthritis: a case report and review of the literature. Rheumatology International. 2013; 33: 2927-30.
    DOI  |   Google Scholar
  8. Brummer T, Ruck T, Meuth SG, Zipp F, Bittner S. Treatment approaches to patients with multiple sclerosis and coexisting autoimmune disorders. Therapeutic Advances in Neurological Disorders. 2021; 14: 17562864211035542.
    DOI  |   Google Scholar
  9. Venturini M, Zanca A, Venturuzzo A, Filippini M, Frassi M, Tincani A, et al. Secukinumab for patients with plaque psoriasis affected by multiple sclerosis: a mini‐review with a representative case report. Journal of the European Academy of Dermatology and Venereology. 2020; 34(2): e110-2.
    DOI  |   Google Scholar
  10. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. Journal of Investigative Dermatology. 2013; 133(2): 377-85.
    DOI  |   Google Scholar


Most read articles by the same author(s)